The adeno-associated virus-mediated HSV-TK/GCV suicide system: A potential strategy for the treatment of bladder carcinoma

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1938-1947

  Pan, Jian Gang ^a   Zhou, Xing ^a   Luo, Runqi ^a   Han, Rui Fa ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Adeno associated virus; Bladder cancer; Gene therapy; HSV TK

Indexed keywords

ADENOVIRUS VECTOR; DNA POLYMERASE; GANCICLOVIR; THYMIDINE KINASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER GENE THERAPY; CELL GROWTH; CONTROLLED STUDY; DEATH; DNA SYNTHESIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE THERAPY; XENOGRAFT;

ANIMALS; DEPENDOVIRUS; DRUG DELIVERY SYSTEMS; GANCICLOVIR; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; MICE; MICE, INBRED BALB C; SIMPLEXVIRUS; THYMIDINE KINASE; URINARY BLADDER NEOPLASMS; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872799939     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0091-x     Document Type: Article

References (26)

1. Malkowicz SB. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol. 2000;18:280-8.
2. Edelman MJ. New approaches to treatment of metastatic bladder cancer. Curr Oncol Rep. 2000;2:379-85.
3. Block T. Chemotherapy of bladder carcinoma. Current status and trends. Urologe A. 1994;33:557-67.
4. Witjes JA, Wullink M, Oosterhof GO, de Mulder P. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol. 1997;31:414-9.
5. Freund CT, Tong XW, Rowley D, Engehausen D, Frolov A, Kieback DG, et al. Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003;21:197-205.
6. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006;4:218-27.
7. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther. 2005;4:512-7.
8. Li J, Li HM, Zhu L, Song WJ, Li R, Wang DS, Dou KF. The adenovirus-mediated linamarase/linamarin suicide system: a potential strategy for the treatment of hepatocellular carcinoma. Cancer Lett. 2010;289:217-27.
9. Sharma A, Tandon M, Bangari DS, Mittal SK. Adenoviral vectorbased strategies for cancer therapy. Curr Drug Ther. 2009;4: 117-38.
10. Park SY, Lee W, Lee J, Kim IS. Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 2008;261:205-14.
11. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13-26.
12. Mori K, Iwata J, Miyazaki M, Osada H, Tange Y, Yamamoto T, Aiko Y, Tamura M, Shiroishi T. Bystander killing effect of thymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells. Neurol Med Chir (Tokyo). 2010;50:545-53.
13. Paíno T, Gangoso E, Medina JM, Tabernero A. Inhibition of ATPsensitive potassium channels increases HSV-tk/GCV bystander effect in U373 human glioma cells by enhancing gap junctional intercellular communication. Neuropharmacology. 2010;59: 480-91.
14. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules. 2009;14:4517-45.
15. Zhang Y, Ma H, Zhang J, Liu S, Liu Y, Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 2008; 82:1154-61.
16. Ma H, Liu Y, Liu S, Kung HF, Sun X, Zheng D, Xu R. Recombinant adenoassociated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer. 2005;116: 314-21.
17. Streck CJ, Dickson PV, Ng CY, Zhou J, Gray JT, Nathwani AC, Davidoff AM. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clin Cancer Res. 2005;11:6020-9.
18. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 1991;10:3941-50.
19. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release. 2004;94:1-14.
20. AAV Helper-Free System Instruction Manual. Revision A.02. http://www.stratagene.com.
21. Wu X, Dong X, Wu Z, Cao H, Niu D, Qu J, Wang H, Hou Y. A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chin Sci Bull. 2001;6:485-90.
22. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector tool kit for human gene therapy. Mol Ther. 2006; 14:316-27.
23. Pan J, Zhou X, Zeng G, Han R. Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumor Biol. 2011;32(2):301-10.
24. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associate virus vector. J Virol. 2009;70:8098-108.
25. Kyoko H, Lee J, Yoshie M, Naoki T, Hideo N, Toshimitsu H. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J Gen Med. 2006;8:1056-67.
26. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy: role of gap junctional intercellular communication. Cancer Res. 2000;60: 3989-99.